Physician profile
Kyaw Moe
NPI 1083649735
$2,841.99
in general payments reported to CMS, 2019-2025
19 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $379 · 2021: $284 · 2022: $117 · 2023: $371 · 2024: $717 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Education: $16.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.04 |
| Education | $16.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $530.11 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $468.01 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $287.56 | 2020-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $282.86 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $256.38 | 2021-2025 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.35 | 2022-2025 | Jardiance |
| Travere Therapeutics, INC. | $128.07 | 2023 | |
| Bard Peripheral Vascular, INC. | $117.89 | 2023 | Wavelinq |
| Fresenius USA Marketing, INC. | $98.52 | 2022-2024 | Velphoro |
| Alexion Pharmaceuticals, INC. | $89.96 | 2019 | |
| Glaxosmithkline, LLC. | $79.37 | 2019-2023 | Benlysta |
| Ardelyx, INC. | $69.79 | 2024-2025 | Ibsrela |
| Amgen INC. | $63.46 | 2021-2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $53.10 | 2024-2025 | |
| Vifor Pharma, INC. | $43.66 | 2024-2025 | Veltassa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $42.14 | 2023-2025 | Tarpeyo |
| Abiomed | $31.44 | 2025 | |
| Akebia Therapeutics INC | $24.90 | 2025 | Vafseo |
| Janssen Pharmaceuticals, INC | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyaw Moe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.